Annexon Biosciences
Biotechnology ResearchView the employees at
Annexon Biosciences-
Violet Torneros, SHRM CP Exec. Director, People at Annexon Biosciences
-
Brisbane
-
Top 10%
Justin Chun Manager, CMC Operations and Project Management at Annexon Biosciences-
San Francisco, California, United States
-
Rising Star
Noosha Yousefpour Scientist-
San Francisco Bay Area
-
Rising Star
Marta Schumacher ED and Head of Global Clinical Operations at Annexon Biosciences-
San Francisco Bay Area
-
Top 1%
Kris Fortner Corporate Affairs, Communications and Policy Executive-
San Francisco Bay Area
-
Top 10%
Overview
Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders of the body, brain, and eye. The company’s pipeline is based on its platform technology addressing a broad spectrum of well-researched classical complement-mediated autoimmune and neurodegenerative diseases triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is advancing a portfolio of innovative product candidates designed to block the activity of C1q and the entire classical complement pathway: ANX005 (intravenous administration), ANX007 (intravitreal administration), and ANX009 (subcutaneous administration). Annexon is deploying a disciplined, biomarker-driven strategy designed to improve the probability of technical success of its portfolio. For more information, visit www.annexonbio.com.
-